When did United Therapeutics report Q4 2024 earnings?

United Therapeutics (UTHR) reported Q4 2024 earnings on February 26, 2025 before market open.

What were United Therapeutics's Q4 2024 revenue and EPS?

United Therapeutics reported revenue of $735.9M and diluted EPS of $6.19 for Q4 2024.

Did United Therapeutics beat estimates in Q4 2024?

Revenue beat the consensus estimate of $734.7M by $1.2M. EPS missed the consensus estimate of $6.40 by $0.21.

Where can I find United Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001082554-25-000005) directly on SEC EDGAR. The filing index links above go to sec.gov.

United Therapeutics UTHR Q4 2024 Annual earnings

Reported February 26, 2025 · Before market open

Revenue$735.9MBeat by $1.2M Diluted EPS$6.19Miss by $0.21

Revenue estimate$734.7M

EPS estimate$6.40

Next report

Jul 29, 2026 (In 4 days)

Revenue estimate$805.0M

EPS estimate$7.06

Financials

Q4 2024

Income statement

See full

Revenue$735.9M+19.7%

Gross profit$660.0M+21.4%

Operating income$357.7M+37.5%

Net income$301.3M+38.8%

EPS (diluted)$6.21+43.4%

Balance sheet

See full

Cash & equivalents$1.7B+40.5%

Total equity$6.4B+7.7%

Total assets$7.4B+2.7%

Cash flow

See full

Operating cash flow$341.2M+126%

CapEx$86.7M+10.2%

Free cash flow$254.5M+253%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$15.75B+52.4%

P/E13.2×+2.7×

P/S5.5×+1.0×

Profitability

See full

Gross margin89.2%+0.3pp

Operating margin47.9%-3.1pp

Net margin41.5%-0.8pp

FCF margin37.6%+5.4pp

Returns & leverage

See full

Return on equity19.2%+1.0pp

Current ratio5.2×+0.8×

Segments

By product

See full

Tyvaso DPI$273.2M+27.8%

Nebulized Tyvaso$142.7M+4.2%

Remodulin$134.5M+16.9%

Orenitram$107.8M+28.2%

Unituxin$67.5M+24.5%

By geography

See full

U.S.$705.7M+20.4%

Versus estimates

Revenue

Q1 2026$781.5MMiss by $15.9M Q4 2025$790.2MMiss by $22.9M Q3 2025$799.5MMiss by $15.3M Q2 2025$798.6MMiss by $3.3M Q1 2025$794.4MBeat by $15.7M

Q4 2024$735.9MBeat by $1.2M

Diluted EPS

Q1 2026$5.82Miss by $1.18 Q4 2025$7.70Beat by $0.57 Q3 2025$7.16Beat by $0.27 Q2 2025$6.41Miss by $0.88 Q1 2025$6.63Beat by $0.34

Q4 2024$6.19Miss by $0.21

Ask the moment United Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did United Therapeutics report Q4 2024 earnings?: United Therapeutics (UTHR) reported Q4 2024 earnings on February 26, 2025 before market open.
What were United Therapeutics's Q4 2024 revenue and EPS?: United Therapeutics reported revenue of $735.9M and diluted EPS of $6.19 for Q4 2024.
Did United Therapeutics beat estimates in Q4 2024?: Revenue beat the consensus estimate of $734.7M by $1.2M. EPS missed the consensus estimate of $6.40 by $0.21.
Where can I find United Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001082554-25-000005) directly on SEC EDGAR. The filing index links above go to sec.gov.